Large South Korean pharma firms have reported mixed second-quarter earnings amid the ongoing medical care disruption in the country stemming from the prolonged standoff between the government and medical community.
Given the meteoric rise of obesity drugs globally, more companies in the country are also progressing their assets in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?